A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
Status:
Terminated
Trial end date:
2020-08-06
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, placebo-controlled, parallel-group study to assess
safety and efficacy of ZPL389 in subjects with moderate to severe atopic dermatitis with a
total study duration up to 24 weeks